NON-HODGKIN'S LYMPHOMAS IN CHILDREN: CLINICAL PICTURE, DIAGNOSIS, TREATMENT


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Non-Hodgkin’s lymphomas (NHL) occupy the third place in the structure of oncological morbidity in children and are characterized by highly aggressive course. Rapid dissemination and the development of life-threatening complications determine the need to identify the type of lymphoma and tactics of management of a patient as soon as possible. The article concerns the theories of etiology, the features of the clinical picture, examination and treatment of the main morphological variants of NHL. Over the past decades, the approach to diagnosis and treatment of diseases in this group has changed significantly. Currently, special attention is paid to immunohistochemical and cytogenetic characteristics. Modern therapy taking into account these features of the disease has made it possible to achieve distinct successes, which resulted in a significant increase in the survival rate of pediatric patients.

Full Text

Restricted Access

About the authors

S. A Kuleva

N.N. Petrov National Medical Research Center of Oncology

Email: Kulevadoc@yandex.ru
MD, Leading Scientist at the Scientific department of Innovative Methods of Therapeutic Oncology and Rehabilitation, Head of the Department of Chemotherapy and Combined Treatment of Malignant Tumors in Children

A. A Gogun

N.N. Petrov National Medical Research Center of Oncology

References

  1. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Федеральные клинические рекомендации по диагностике и лечению неходжкинских лимфом. М., 2015. 47 с.
  2. Hochberg J., Waxman I., Keiiy K., et al. Adolescent non-Hodgkin's lymphoma and Hodgkin's lymphoma: state of the science. Br. J. Haematol. 2009;144(1):24-40.
  3. Киселев А.В., Махонова Л.А., Петерсон И.С. и др. Неходжкинские лимфомы. В. кн.: Злокачественные новообразования кроветворной и лимфоидной ткани у детей. М., 2001. С. 187-203.
  4. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Lyon: IARS Press; 2008. 439 р.
  5. Burhart B., Zimmermann M., Oschlies I., et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br. J. Haematol. 2005;131:(1):39-49.
  6. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. Pathology and Getetics of Tumours of Haematopoietic and Lymphoid tissues. IARS Press Lyon. 2001. 351 p.
  7. Rolink A.G., Schaniek C., Andersson J., et al. Selection events operating et varios stages in B-cell development. Curr. Opin. Immunol. 2001; 13:202-7.
  8. Гематология: национальное руководство / Под ред. О.А. Рукавицина М., 2015. 776 с.
  9. Kramer S., Hikel S., Adams K., et al. Current status of the epidemiologic evidence linking polychlorinated biphenyls and non-Hodgkin lymphoma, and the role of immune dysregulation. Environmental Health Perspectives. 2012. 1067 р.
  10. Tsokos G.C., Balow S.E., Spiegel R.J., et al. Renal and metabolic complications of undifferentiated and lymphoblastic lymphoma. Pediatrics. 1988; 83:863-69.
  11. Murphy S.B., Bowman W.P., Abromowitch M., et al. Results of treatment of advanced - stage Burkitt's lymphoma and B-cell (sIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J. Clin. Oncol. 1991;9:123-32.
  12. Margath I. B-cell lymphoma/Burkitt lymphoma. Springer Verlag Berlin, Heidelberg, 2007:142-52.
  13. Сотникова О.П., Сорокин Е.Н., Поддубная И.В. Первичные неходжкинские лимфомы яичка. Онкоурология. 2012;1:88-93.
  14. Валиев Т.Т., Ковригина А.М., Ключагина Ю.И., Сендерович А.И. Опыт цитогенетических исследований при неходжкинских лимфомах у детей. Онкопедиатрия. 2016;3(2):130.
  15. Барях Е.А., Кравченко С.К., Обухова Т.Н., и др. Лимфома Беркитта: клиника, диагностика, лечение. Клиническая онкогематология. 2009;2(2):137-46.
  16. Валиев Т.Т. Современная стратегия диагностики и лечения неходжкинских лимфом у детей. Дисс. докт. мед. наук. М., 2014.
  17. Croce C. Role of chromosome translocations in human neoplasia. C. Croce. Cell. 1987;49(2): 155-56.
  18. Love S., Sun Z., Jima D. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 2012;44(12):1321-25.
  19. Graux C., Cols J., Michaux L., et al. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496-510.
  20. Лейкозы у детей. Под ред. Г.Л. Менткевича, С.А. Маяковой. М., 2009. 381 с.
  21. Смирнова Н.В., Мякова Н.В., Белогурова М.Б. и др. Лечение зрелоклеточных В-клеточных неходжкинских лимфом с использованием комбинированной иммунохимиотерапии: возможности оптимизации терапевтической стратегии. Онкогематология. 2015;10(4):15-24.
  22. Aukema S.M., Siebert R., Schuuring E., et al. Double-hit B-cell lymphomas. Blood. 2011;117(8): 2319-31.
  23. Swerdlow S., Campo E., Harris N.L., et al. The international Agency for research on cancer. WHO classification of tumours of haematopoietic and lymphoid tissues (IARS WHO Classification of Tumours). Lyn eds. WHO, 2008.
  24. Mussolin L., Pillon M., Bonato P., et al. Cytogenetic analysis of pediatric anaplastic large cell lymphoma. Pediatr. Blood Cancer. 2010;55(3):446-51.
  25. Ferreri A.J., Govi S., Pileri S.A., et al. Anaplastic large cell lymphoma, ALK-negative. Crit. Rev. Oncol. Hematol. 2013;85:(2):206-15.
  26. Murphy S.B. Prognostic features and obstacles to cure of childhood non-Hodgkin's lymphoma. Sem. Oncol. 1977;4:265.
  27. Valiev T.T. T- and B-cell lymphomas in children: clinical and immunological features, results of treatment. Hematologica. 14th Congress of the European Hematology Association. Berlin, Germany, June4-7, 2009;94(2):176.
  28. Reiter A., Schrappe M., Tiemann M., et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM-90. Blood. 1999:94(10):3294-306.
  29. Валиев Т.Т., Барях Е.А. Эволюция взглядов на диагностику и лечение лимфомы Беркитта. Онкогематология. 2014;1(7):46-56.
  30. Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б., Шамардина А.В. и др. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ 2004 М. с применением ритуксимаба и модифицированного протокола В-НХЛ БФМ-90. Онкогематология. 2009;3:4-1.
  31. Тумян Г.С., Заводнова И.З., Кичигина М.Ю. и др. Первичная медиастинальная (тимическая) В-крупноклеточная лимфома. Клиническая онкогематология. 2017;10(1):20-2.
  32. Seidemann K., Tiemann M., Lauterbach I., et al. Primery mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-M nster Group. J. Clin. Oncol. 2003;21(9):1782-19.
  33. Asselin B.L., Devidas M., Wang C., et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood. 2011;118(4):874-83.
  34. Dunsmore K.P., Devidas M., Linda S.B., et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J. Clin. Oncol. 2012;30(22):2753-59.
  35. Cooper T.M., Razzouk B.I., Gerbing R., et al. Phase I/ll trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group. Pediat. Blood Cancer. 2013;60(7): 1141-47.
  36. Валиев Т.Т., Морозова О.В., Ковригина А.М. и др. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология. 2012;57(1):3-9.
  37. Bonvini P., Gastaldi T., Falini B., et al. Nucleophosminanaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK+ CD30+ lymphoma cells by Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 2002;62(5):1559-66.
  38. Han Y., Amin H.M., Franko B., et al. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteasome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood. 2006;108(8):2796-803.
  39. Ogura M., Tobinai K., Hatake K., et al. Phase I/ll study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840-46. doi: 10.1111/cas.12435.
  40. Mosse Y.P., Lim M.S., Voss S.D., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472-80.
  41. Goldberg J.D., Casulo C., Horwitz S.M. The role of hematopoietic stem cell transplantation in peripheral T-cell lymphomas. In: Non-Hodgkin Lymphoma Cancer Drug Discovery and Development. Springer, 2013. P. 279-93.
  42. Brugieres L., Le Deley M.C., Rosolen A., et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J. Clin. Oncol. 2009;27(6):897-903.
  43. Samochatova E., Myakova N., Shelikhova L., et al. Preliminary results of treatment of pediatric advance-staged mature В-cell non-Hodgkin lymphomas/B-ALL with intensive chemotherapy+rituximab: effectiveness and toxicity. Pediatr. Blood Cancer. 2006;46(issue 7):854.
  44. Okur F.V., Oguz A., Karadenis C., et al. Refractoriness to rituximab monotherapy in a child with relapsed/ refractory Burkitt non-Hodgkin lymphoma. Pediatr. Hematol. Oncol. 2006;23(1):25-31.
  45. Plosker G.L., Figgit D.P. Rituximab. Drugs. 2003;63(8):803-43.
  46. Kim J.E., Yoon D.H., Jang G., et al. A phase // II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. Korean J. Hematol. 2012; 47(1):53-9.
  47. Foyil K.V., Bartlett N.L. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunother. 2011;3(4):475-85.
  48. Raetz E.A., Cairo M.S., Borowitz M.J., et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J. Clin. Oncol. 2008;26(22):3756-62.
  49. Cooney-Qualter E., Krailo M., Angiolillo A., et al. A Phase I. Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin's Lymphoma: A Children's Oncology Group Study. Clin. Cancer Res. 2007;13(18):5662-60.
  50. Виноградова Ю.И., Ильин Н.В. Лучевая терапия в комбинированном лечении неходжкинских лимфом. Злокачественные опухоли. 2015;2(16):44-
  51. Валиев Т.Т., Попа А.В. Клинические рекомендации по диагностике и лечению детей, больных неходжкинскими лимфомами. Общероссийский Союз Общественных Объединений Ассоциация Онкологов России. М., 2014. 9 с.
  52. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. М., 2009. 447 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies